Multiple Myeloma
Conditions
Keywords
multiple myeloma, proteasome inhibitor, relapsed, refractory
Brief summary
This is a Phase 2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 (also known as marizomib) in patients with relapsed or relapsed/refractory multiple myeloma. NPI-0052 is a novel, second generation proteasome inhibitor that prevents the breakdown of proteins involved in signal transduction which blocks growth and survival in cancer cells. The study is a Phase 2 study and is a 2-stage efficacy design in a selected subgroup of patients (Arm C) treated with the recommended phase 2 dose of NPI-0052, as determined in a previously completed Phase 1 study. The study is to evaluate the safety and any preliminary evidence of efficacy of NPI-0052 in multiple myeloma patients who have previously received carfilzomib (PR-171, Kyprolis™) and subsequently had disease progression.
Interventions
DRUGMRZ 0.5 mg/m^2
NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
Sponsors
Celgene
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Prior to Amendment 13: * Age 18 years. * Karnofsky Performance Status (KPS) score 70%. * All patients must have histologic evidence of multiple myeloma. Evidence of relapsed or relapsed/refractory disease for which no other approved treatment is available and clinically indicated. In addition, patients may have undergone prior bone marrow transplantation. For patients treated at the Recommended Phase 2 Dose patients are required to have measurable relapsed or relapsed/refractory disease. Disease must be assessed within 28 days prior to treatment initiation. 1. Measurable disease is defined as one of the following: * Serum M-protein ≥0.5 g/dL * Urine M-protein ≥200 mg/24 hours * Involved serum free light chain (FLC) level ≥10 mg/dL, provided the serum FLC ratio is abnormal 2. Relapsed and Refractory are defined as: * Must have received at least 2 prior treatment regimens. * Must have received prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of bortezomib (either in separate regimens or within the same regimen). * Must have received a cytotoxic chemotherapy agent (eg, alkylating agent). * Relapsed Disease: Must have progressive disease after having achieved at least stable disease for at least one cycle of treatment during at least one prior regimen. * Refractory Disease: Must have documented evidence of progressive disease during or within 60 days (measured from the end of the last cycle) of completing the most recently received anti-myeloma drug regimen prior to study entry * All AEs resulting from prior chemotherapy, surgery, or radiotherapy must have resolved to NCI-CTCAE Grade 1 (except for hematologic parameters outlined below). * The following laboratory results, within 7 days prior to NPI-0052 administration (transfusions and/or growth factor support may be used with discretion by the Investigator during Screening): * Hemoglobin 8 g/dL * Absolute neutrophil count 0.5 × 109/L * Platelet count 30 × 109/L * Serum bilirubin 1.5 × ULN * AST 2.5 × ULN * Serum creatinine 1.5 × ULN * Creatinine clearance ≥40 mL/min * Signed informed consent. * Must have previously received at least 2 cycles of carfilzomib (as a single agent or in combination with other agents) and subsequently had disease progression during or within 60 days of carfilzomib therapy. Carfilzomib does not have to be the most recent therapy that the patient has received, but patients must have documented disease progression during or within 60 days of their last anti-myeloma therapy Inclusion Criteria Amendment 13: * Age 18 years. * Karnofsky Performance Status score 70%. * All patients must have histologic evidence of multiple myeloma and evidence of relapsed or relapsed/refractory disease as defined below Patients are required to have measurable relapsed or relapsed/refractory disease. Disease must be assessed within 28 days prior to treatment initiation. 1. Measurable disease defined as one of the following: * Serum M-protein ≥0.5 g/dL * Urine M-protein ≥200 mg/24 hours * Involved serum free light chain (FLC) level ≥10 mg/dL provided the serum FLC ratio is abnormal 2. Relapsed and Refractory are defined as: * Must have received at least 2 prior treatment regimens. * Must have received prior treatment with at least 2 cycles of an immunomodulator (lenalidomide or pomalidomide or thalidomide). * Must have previously received at least 2 cycles of carfilzomib (as a single agent or in combination with other agents) and subsequently had disease progression during or within 60 days of carfilzomib therapy. Carfilzomib does not have to be the most recent therapy that the patient has received, but patients must have documented disease progression during or within 60 days of their last anti-myeloma therapy. Patients may also have received bortezomib. In addition, patients may have undergone prior cytotoxic chemotherapy, bone marrow transplantation and previously participated in other clinical trials. * Relapsed Disease: Must have progressive disease after having achieved at least stable disease for at least one cycle of treatment during at least one prior regimen. * Refractory Disease: Must have documented evidence of progressive disease during or within 60 days (measured from the end of the last cycle) of completing the most recently received anti-myeloma drug regimen prior to study entry. * All Adverse Events resulting from prior chemotherapy, surgery, or radiotherapy, must have resolved to CTCAE Grade 1 (except for hematologic parameters outlined below). * The following laboratory results, within 7 days of NPI-0052 administration (transfusions and/or growth factor support may be used with discretion by the Investigator during the screening period): * Hemoglobin 8 g/dL * Absolute neutrophil count 0.5 x 109/L * Platelet count 30 x 109/L * Serum bilirubin 1.5 x ULN * AST 2.5 x ULN * Serum creatinine 1.5 x ULN * Creatinine clearance ≥40 mL/min -Signed informed consent.
Exclusion criteria
* Administration of chemotherapy, biological, immunotherapy, or investigational agent (therapeutic or diagnostic) within 14 days prior to receipt of study medication (this washout period can be reduced to 7 days for biologically targeted therapies (eg, bortezomib, carfilzomib, thalidomide, lenalidomide, pomalidomide, and dexamethasone or equivalent), provided the patient has recovered from the toxicity from these regimens per Inclusion Criterion #4). Patients must be 6 weeks from last dose of nitrosourea and 12 weeks from BMT. Patients must be 2 weeks from last dose of radiation. * Patients with Grade \>1 proteinuria (1 g/24 hour excluding M proteins = urine paraprotein subtracted from total urine protein), untreated urinary tract infection, as well as any pre existing kidney disease (acute or chronic) that in the Investigator's assessment would impose excessive risk to the patient. * Patients with evidence of mucosal or internal bleeding and/or platelet refractory (ie, unable to maintain platelet count 30 × 109/L). * Significant cardiac disease defined as: * Patients with congenital long QT syndrome; * Congestive heart failure of Class III or IV of the NYHA classification; * History of myocardial infarction or ischemia within 12 months of study enrollment. * Abnormal left ventricular ejection fraction (LVEF) (\< lower limit of normal as defined by the study site for a patient of that age) by echocardiogram (ECHO) or multiple-gated angiography (MUGA). * Patients with a prior hypersensitivity reaction of CTCAE Grade \>3 to therapy containing propylene glycol or ethanol. * Pregnant or breast-feeding women. Female patients must be postmenopausal or surgically sterile, or they must agree to use acceptable methods of birth control (ie, a hormonal contraceptive with barrier method, intra-uterine device, diaphragm with spermicidal or condom with spermicide, or abstinence) for the duration of the study and for one month following study completion. Female patients with childbearing potential must have a negative serum pregnancy test within the 7 days before the first NPI-0052 administration. Male patients must be surgically sterile or agree to use an acceptable method of contraception. * Active uncontrolled bacterial or fungal infection requiring systemic therapy; infection requiring parenteral antibiotics. * Known to be HIV positive or positive and active for hepatitis A, B, or C. * Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient. Examples of such conditions include infection requiring parenteral or oral anti-infective treatment or any altered mental status or psychiatric condition that would interfere with an understanding of the informed consent. * Unwilling or unable to comply with procedures required in this protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Through study completion, an average of 6.09 weeks. | Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Cycles of Marizomib (MRZ) | Through study completion, an average of 6.09 weeks. | — |
| Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Through study completion, an average of 6.09 weeks. | A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle. |
| Duration of MRZ Treatment | Through study completion, an average of 6.09 weeks. | Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks. |
| Number of Treatment Emergent Adverse Events (TEAEs) | Through study completion, an average of 6.09 weeks. | Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug. Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship. |
| Maximum Observed Blood Drug Concentration (Cmax) | Samples collected on Cycle 1 Day 1 and Cycle 1 Day 11. | — |
| Number of Patients With Treatment Emergent Adverse Events (TEAEs) | Through study completion, an average of 6.09 weeks. | Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug. Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| MRZ 0.5 mg/m^2 Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles | 15 |
| Total | 15 |
Baseline characteristics
| Characteristic | MRZ 0.5 mg/m^2 |
|---|---|
| Age, Continuous | 61.9 years STANDARD_DEVIATION 8.02 |
| Baseline Height | 170.97 cm STANDARD_DEVIATION 12.152 |
| Baseline Weight | 77.27 kg STANDARD_DEVIATION 17.825 |
| Body Surface Area (BSA) | 1.893 m^2 STANDARD_DEVIATION 0.2629 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 15 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Fertility Status Male | 10 Participants |
| Fertility Status Post menopausal | 4 Participants |
| Fertility Status Potential able to bear children | 0 Participants |
| Fertility Status Surgically sterile | 1 Participants |
| Karnofsky Performance Status (KPS) Score | 87.3 KPS Score |
| Number of Relapses 1 Relapse | 0 participants |
| Number of Relapses 2 Relapses | 2 participants |
| Number of Relapses >3 Relapses | 11 participants |
| Number of Relapses 3 Relapses | 2 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 10 Participants |
| Region of Enrollment United States | 15 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 10 Participants |
| Time Since Initial Diagnosis | 5.2 years STANDARD_DEVIATION 3.79 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 15 / 15 |
| serious Total, serious adverse events | 7 / 15 |
Outcome results
Primary
Number of Patients Exhibiting a Given Overall Response as Determined by Investigator
Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR.
Time frame: Through study completion, an average of 6.09 weeks.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Stringent Complete Response (sCR) or better | 0 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Very Good Partial Response (VGPR) | 0 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Complete Response (CR) | 0 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Partial Response (PR) | 0 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Minimal Response (MR) | 0 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Stable Disease (SD) | 4 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Progressive Disease (PD) | 9 participants |
| MRZ 0.5 mg/m^2 | Number of Patients Exhibiting a Given Overall Response as Determined by Investigator | Not Evaluated | 2 participants |
Secondary
Duration of MRZ Treatment
Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks.
Time frame: Through study completion, an average of 6.09 weeks.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MRZ 0.5 mg/m^2 | Duration of MRZ Treatment | 6.09 weeks | Standard Deviation 4.661 |
Secondary
Maximum Observed Blood Drug Concentration (Cmax)
Time frame: Samples collected on Cycle 1 Day 1 and Cycle 1 Day 11.
Population: The sponsor elected not to analyze the pharmacokinetic (PK) samples collected, therefore, no PK results are obtained.
Secondary
Number of Cycles of Marizomib (MRZ)
Time frame: Through study completion, an average of 6.09 weeks.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MRZ 0.5 mg/m^2 | Number of Cycles of Marizomib (MRZ) | 2.6 cycles | Standard Deviation 1.45 |
Secondary
Number of Patients Receiving Marizomib (MRZ) in Each Cycle
A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle.
Time frame: Through study completion, an average of 6.09 weeks.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| MRZ 0.5 mg/m^2 | Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Cycle 5 | 2 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Cycle 6 | 1 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Cycle 1 | 15 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Cycle 2 | 12 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Cycle 3 | 6 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients Receiving Marizomib (MRZ) in Each Cycle | Cycle 4 | 3 Participants |
Secondary
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug. Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship.
Time frame: Through study completion, an average of 6.09 weeks.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one TEAE | 15 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one NPI-0052 related TEAE | 13 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one grade ≥3 TEAE | 12 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one treatment related TEAE | 14 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one treatment related grade ≥3 TEAE | 8 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one NPI-0052 related grade ≥3 TEAE | 5 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one serious TEAE | 7 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one treatment related serious TEAE | 4 Participants |
| MRZ 0.5 mg/m^2 | Number of Patients With Treatment Emergent Adverse Events (TEAEs) | At least one NPI-0052 related serious TEAE | 1 Participants |
Secondary
Number of Treatment Emergent Adverse Events (TEAEs)
Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug. Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship.
Time frame: Through study completion, an average of 6.09 weeks.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of treatment related serious TEAEs | 5 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of NPI-0052 related serious TEAEs | 1 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of TEAEs | 149 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of treatment related TEAEs | 73 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of NPI-0052 related TEAEs | 50 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of grade ≥3 TEAEs | 41 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of treatment related grade ≥3 TEAEs | 16 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of NPI-0052 realted grade ≥3 TEAEs | 9 TEAEs |
| MRZ 0.5 mg/m^2 | Number of Treatment Emergent Adverse Events (TEAEs) | Number of serious TEAEs | 21 TEAEs |